



Supplementary Information for

Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews

Moustafa A. Gadalla, M.Sc.^{1,2*}, Robert J. Norman, M.D., FRANZCOG.², Chau T Tay, Ph.D.^{3,4}, Danielle S. Hiam, Ph.D.⁵, Angela Melder, Ph.D.³, Jyotsna Pundir, M.D., Ph.D.⁶, Shakila Thangaratnam, Ph.D.⁷, Helena J Teede, Ph.D.^{3,4}, Ben W. J. Mol, M.D., Ph.D.^{2,8}, Lisa J. Moran, Ph.D.^{2,3}

1. Women's Health Hospital, Department of Obstetrics and Gynaecology, Assiut University, Assiut, Egypt

2. Robinson Research Institute, Discipline of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia

3. Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Victoria, Melbourne, Australia

4. Monash Diabetes and Endocrinology Units, Monash Health, Victoria, Melbourne, Australia

5. Institute of Sport, Exercise and Active Living, Victoria University, Melbourne, Australia

6. Centre of Reproductive Medicine, St Bartholomew's Hospital, London, United Kingdom

7. Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom

8. Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Melbourne, Australia

Appendix 1: Search strategy

MEDLINE

1. exp Polycystic Ovary Syndrome/
2. Polycystic Ovar\$.tw
3. pco.tw or pcos.tw
4. (sclerocystic adj3 ovar\$.tw
5. stein leventhal.tw
6. or/1-5
7. Meta-Analysis as Topic/
8. meta analy\$.tw
9. metaanaly\$.tw
10. Meta-Analysis/
11. (systematic adj (review\$1 or overview\$1)).tw.
12. exp Review Literature as Topic/
13. or/7-12
14. cochrane.ab.
15. embase.ab.
16. (psychlit or psyclit).ab.
17. (psychinfo or psycinfo).ab.
18. (cinahl or cinhal).ab.
19. science citation index.ab.
20. bids.ab.
21. cancerlit.ab.
22. or/14-21
23. reference list\$.ab.
24. bibliograph\$.ab.
25. hand-search\$.ab.
26. relevant journals.ab.
27. manual search\$.ab.

*Corresponding Address: Department of Obstetrics and Gynecology, "Filippo Del Ponte" Hospital, University of Insubria, Piazza Biroldi 1, 21100, Varese, Italy
Email: antoniosimone.lagana@uninsubria.it

28. or/23-27
29. selection criteria.ab.
30. data extraction.ab.
31. 29 or 30
32. Review/
33. 31 and 32
34. Comment/
35. Letter/
36. Editorial/
37. animal/
38. human/
39. 37 not (37 and 38)
40. or/34-36,39
41. 13 or 22 or 28 or 33
42. 6 and 41
43. 42 not 40

Embase

1. exp Polycystic Ovary Syndrome/
2. Polycystic Ovar\$.tw
3. pco.tw or pcos.tw
4. (sclerocystic adj3 ovar\$.tw
5. stein leventhal.tw
6. or/1-5
7. exp Meta Analysis/
8. (meta adj analy\$.tw
9. metaanalys\$.tw.
10. (systematic adj (review\$1 or overview\$1)).tw.
11. or/7-10
12. cancerlit.ab.
13. cochrane.ab.
14. embase.ab.
15. (psychlit or psyclit).ab.
16. (psychinfo or psycinfo).ab.
17. (cinahl or cinhal).ab.
18. science citation index.ab.
19. bids.ab.
20. or/12-19
21. reference lists.ab.
22. bibliograph\$.ab.
23. hand-search\$.ab.
24. manual search\$.ab.
25. relevant journals.ab.
26. or/21-25

27. data extraction.ab.
28. selection criteria.ab.
29. 27 or 28
30. review.pt.
31. 29 and 30
32. letter.pt.
33. editorial.pt.
34. animal/
35. human/
36. 34 not (34 and 35)
37. or/32-33,36
38. 11 or 20 or 26 or 31
39. 6 and 38
40. 39 not 37

Cinahl

1. MH "Polycystic Ovary Syndrome+"
2. TX Polycystic Ovar*
3. TX pco
4. TX pcos
5. TX stein leventhal
6. TX (sclerocystic n3 ovar*)
7. or/1-6
8. MH "Meta analysis+"
9. TX Meta analys*
10. TX Metaanaly*
11. MH "Literature review+"
12. TX (systematic adj (review or overview))
13. Or/8-12
14. PT Commentary
15. PT Letter
16. PT Editorial
17. MH "Animals+"
18. Or/14-17
19. 7 and 13
20. 19 not 18

PROSPERO

1. "PCOS"
2. "polycystic ovary syndrome"
3. 1 OR 2
4. TI 3

Appendix 2: Excluded studies

| N. | ID | Author | Title | Excluded | Category | Notes |
|-----------|-----------|--------------------------------------|---|-----------------|---------------------------------|---|
| 1. | 1701 | Abu Hashim (1), 2016 | Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence? | Yes | Fertility treatment | Didn't include quality assessment |
| 2. | 1704 | Al Khalifah et al. (2), 2015 | The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol | Yes | | Protocol only |
| 3. | | Al-Khalifah et al. (3), 2016 | The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis. | Yes | | Conference abstract only , no related publication found No available online reference |
| 4. | 2179 | Andrade (4), 2016 | Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy. | Yes | | Not an original systematic review or meta-analysis |
| 5. | 1714 | Atiomo et al. (5), 2009 | Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: a systematic review | Yes | Assessment | Didn't include quality assessment |
| 6. | 1722 | Bagos (6), 2009 | Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 7. | 1723 | Bao et al. (7), 2016 | Association of DENND1A Gene Polymorphisms with Polycystic Ovary Syndrome: A Meta-Analysis | Yes | | Didn't include quality assessment |
| 8. | 1725 | Baranova et al. (8), 2011 | Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease | Yes | Assessment | Didn't include number of articles extracted on search or quality assessment |
| 9. | 1726 | Barba et al. (9), 2009 | The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis | Yes | Non-fertility medical treatment | Not primarily focused on PCOS |
| 10. | 1444 | Bayram et al. (10) 2010 | Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome | Yes | Fertility treatment | Although Cochrane assessed content as up to date in 2010, search was conducted in 2003 so deemed this as meeting prior to 2009 exclusion criteria |
| 11. | 1744 | Birch Petersen et al. (11), 2016 | Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction | Yes | Fertility treatment | Didn't include search terms or number of articles extracted on search |
| 12. | 1428 | Bouza-Alvarez et al. (12), 2011 | Safety and efficacy of metformin in improving clinical, hormonal and metabolic features of polycystic ovary syndrome. Systematic review and meta-analysis | Yes | | ? HTA, bulk of article in Spanish |
| 13. | 1750 | Bronstein et al. (13), 2011 | Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought | Yes | Assessment | Didn't include quality assessment |
| 14. | 1754 | Cahill (14), 2009 | PCOS | Yes | | Didn't include search terms or number of articles extracted on search |
| 15. | 1755 | Cahill and <i>O'Brien</i> (15), 2015 | Polycystic ovary syndrome (PCOS): metformin | Yes | | Didn't include search terms or number of articles extracted on search |
| 16. | 1756 | Cai et al. (16), 2014 | Association between fat mass- and obesity-associated (FTO) gene polymorphism and polycystic ovary syndrome: a meta-analysis | Yes | | Didn't include quality assessment |

Appendix 2: Continued

| | | | | | | |
|-----|------|--|---|-----|---------------------------------|---|
| 17. | 1758 | Carlus et al. (17), 2016 | Is MTHFR 677 C>T Polymorphism Clinically Important in Polycystic Ovarian Syndrome (PCOS)? A Case-Control Study, Meta-Analysis and Trial Sequential Analysis | Yes | | Didn't include quality assessment |
| 18. | 1763 | Chen et al. (18), 2014 | Two follicle-stimulating hormone receptor polymorphisms and polycystic ovary syndrome risk: a meta-analysis | Yes | | Didn't include quality assessment |
| 19. | 1766 | Chittenden et al. (19), 2009 | Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review | Yes | Assessment | Didn't include quality assessment |
| 20. | 1341 | Conte et al. (20), 2015 | Mental Health and Physical Activity in Women with Polycystic Ovary Syndrome: A Brief Review | Yes | | Didn't include quality assessment |
| 21. | 1466 | Costello et al. (21), 2010 | Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome | Yes | Non-fertility medical treatment | No update of search strategy since 2006 |
| 22. | 1478 | Dissemination (22) | Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss | Yes | | Didn't include number of articles extracted on search or quality assessment |
| 23. | 1481 | Dissemination (23) | N-acetylcysteine for treating women with clomiphene citrate resistant polycystic ovary syndrome: a systematic review | Yes | | Not in English |
| 24. | 1525 | Dissemination (24) | Rosiglitazone versus metformin for polycystic ovary syndrome: a systematic review (Provisional abstract) | Yes | | Not in English |
| 25. | 1491 | Dissemination (25) | Efficacy of inositol in women with polycystic ovary syndrome and desire for children: systematic review and meta-analysis | Yes | | Not in English |
| 26. | 1539 | Dissemination (26), 2015 | Letrozole for ovulation induction in women with polycystic ovarian syndrome: a systematic analysis | Yes | | Not in English |
| 27. | 1518 | Dissemination (27), 2015 | Thiazolidinediones combined with metformin in treatment of polycystic ovary syndrome: a systematic review | Yes | | Not in English |
| 28. | 1540 | Dissemination (28), 2015 | Laparoscopic surgery versus laparotomy for women with polycystic ovarian syndrome: a systematic review. | Yes | | Not in English |
| 29. | 1786 | Dokras et al. (29), 2011 | Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis | Yes | Assessment | Didn't include quality assessment |
| 30. | 1794 | Du et al. (30), 2010 | Two FSHR variants, haplotypes and meta-analysis in Chinese women with premature ovarian failure and polycystic ovary syndrome | Yes | | Didn't include search terms, quality assessment or number of articles extracted on search |
| 31. | 1793 | Du and Li (31), 2013 | The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis | Yes | Assessment | Didn't include quality assessment |
| 32. | 1799 | Eckmann and Kockler (32), 2009 | Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome | Yes | Fertility treatment | Didn't include number of articles extracted on search or quality assessment |
| 33. | 1804 | Escobar-Morreale et al. (33), 2011 | Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis | Yes | Assessment | Didn't include quality assessment |
| 34. | 1323 | Escobar-Morreale and Roldán-Martín (34), 2016 | Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis | Yes | | did not address PCOS co-morbidities |
| 35. | 1806 | Eyvazzadeh (35), 2009 | The role of the endogenous opioid system in polycystic ovary syndrome | Yes | | Not an original systematic review or meta-analysis |
| 36. | 1807 | Fan et al. (36), 2013 | Association between the (TAAAA) _n SHBG polymorphism and PCOS: a systematic review and meta-analysis | Yes | | Didn't include quality assessment |

Appendix 2: Continued

| | | | | | | |
|-----|------|-----------------------------------|--|-----|--------------------------|---|
| 37. | 1572 | Farquhar et al. (37), 2009 | Laparoscopic ovarian diathermy versus metformin for women with polycystic ovarian syndrome | Yes | Protocol only, no review | Protocol only |
| 38. | 1818 | Fernandez et al. (38), 2011 | Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review | Yes | Fertility treatment | Didn't include quality assessment |
| 39. | 1825 | Frary et al. (39), 2016 | The effect of dietary carbohydrates in women with polycystic ovary syndrome: a systematic review. | Yes | Lifestyle treatment | Didn't include quality assessment |
| 40. | 1826 | Fu et al. (40), 2014 | Association of methylenetetrahydrofolate reductase gene C677T polymorphism with polycystic ovary syndrome risk: a systematic review and meta-analysis update | Yes | | Didn't include quality assessment |
| 41. | 1832 | Galazis et al. (41), 2012 | Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration | Yes | | Exclude, PCOS SR component update of Atiomo 2008/9 with no quality assessment |
| 42. | 1831 | Galazis et al. (42), 2012 | Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome | Yes | | Not primarily focused on PCOS |
| 43. | 1833 | Galazis et al. (43), 2013 | Proteomic biomarkers of endometrial cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration | Yes | | Exclude, PCOS SR component update of Atiomo 2008/9 with no quality assessment |
| 44. | 1829 | Galazis et al. (44), 2013 | Proteomic biomarkers of preterm birth risk in women with polycystic ovary syndrome (PCOS): a systematic review and biomarker database integration | Yes | | Exclude, PCOS SR component update of Atiomo 2008/9 with no quality assessment |
| 45. | 1834 | Gao et al. (45), 2012 | Association of the T45G and G276T polymorphisms in the adiponectin gene with PCOS: A meta-analysis | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 46. | 2180 | Garg and <i>Merhi (46)</i> , 2016 | Relationship between advanced glycation end products and steroidogenesis in PCOS. | Yes | | Not an original systematic review or meta-analysis |
| 47. | 2188 | Genazzani (47), 2016 | Inositol as putative integrative treatment for PCOS | Yes | | Not an original systematic review or meta-analysis |
| 48. | 1404 | Groth (48), 2010 | Adiponectin and Polycystic Ovary Syndrome | Yes | Assessment | Didn't include number of articles extracted on search or quality assessment |
| 49. | 2186 | Gu et al. (49), 2016 | The association between paraoxonase 1 gene polymorphisms and polycystic ovarian syndrome. | Yes | Genetics | Didn't include quality assessment or number of articles extracted on search |
| 50. | 1855 | Haoula et al. (50), 2012 | Evaluating the association between endometrial cancer and polycystic ovary syndrome | Yes | Assessment | Didn't include quality assessment |
| 51. | 1864 | He et al. (51), 2012 | A meta-analysis on the association between PPAR-gamma Pro12Ala polymorphism and polycystic ovary syndrome | Yes | | Didn't include quality assessment |
| 52. | 1873 | Huang et al. (52), 2012 | Four polymorphisms of the CAPN 10 gene and their relationship to polycystic ovary syndrome susceptibility: a meta-analysis | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 53. | 1883 | Ioannidis et al. (53), 2010 | Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 54. | 1886 | Jalilian et al. (54), 2015 | Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: A meta-analysis | Yes | Assessment | Didn't include quality assessment |
| 55. | 1395 | Janci et al. (55), 2012 | Polycystic Ovarian Syndrome: Metformin or Thiazolidinediones for Cardiovascular Risk Reduction? | Yes | | Didn't include number of articles extracted on search or quality assessment |

Appendix 2: Continued

| | | | | | | |
|-----|------|--------------------------------|---|-----|---------------------------------|---|
| 56. | 1888 | Jia et al. (56), 2013 | Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with polycystic ovary syndrome: a meta-analysis | Yes | | Didn't include quality assessment |
| 57. | 1890 | Jia et al. (57), 2014 | Association between retinol-binding protein 4 and polycystic ovary syndrome: a meta-analysis | Yes | Assessment | Didn't include quality assessment |
| 58. | 1893 | Johnson (58), 2011 | Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials | Yes | | Didn't include search terms, number of articles extracted on search or quality assessment |
| 59. | 1902 | Kelly et al. (59), 2011 | Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis | Yes | Assessment | Didn't include quality assessment |
| 60. | 1905 | Khan et al. (60), 2015 | Overlap of proteomics biomarkers between women with pre-eclampsia and PCOS: a systematic review and biomarker database integration | Yes | | Exclude, PCOS SR component update of Atiomo 2008/9 with no quality assessment |
| 61. | 1907 | Kjerulff et al. (61), 2011 | Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis | Yes | Assessment | Didn't include quality assessment |
| 62. | 1909 | Kong et al. (62), 2015 | Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis | Yes | Non-fertility medical treatment | Didn't include quality assessment |
| 63. | 1913 | Krul-Poel et al. (63), 2013 | The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review | Yes | Assessment | Didn't include quality assessment |
| 64. | 1384 | Lai et al. (64), 2014 | Chinese Herbal Medicine for Oligomenorrhoea and Amenorrhoea in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis | Yes | Complementary therapy | Abstract only |
| 65. | 1915 | Lakkakula et al. (65), 2013 | Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review | Yes | | Didn't include search terms, quality assessment or number of articles extracted on search |
| 66. | 1917 | Lautatzis et al. (66), 2013 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review | Yes | Non-fertility medical treatment | Didn't include search terms |
| 67. | 1918 | Lee and <i>Song</i> (67), 2014 | Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 68. | 1937 | Lim and <i>Wong</i> (68), 2010 | Current evidence of acupuncture on polycystic ovarian syndrome. | Yes | Complementary therapy | Didn't include search terms, number of articles extracted on search or quality assessment |
| 69. | 1943 | Lin et al. (69), 2013 | Androgen receptor gene polymorphism and polycystic ovary syndrome | Yes | | Didn't include quality assessment |
| 70. | 1942 | Lin et al. (70), 2014 | Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs | Yes | Fertility treatment | Didn't include quality assessment |
| 71. | 1946 | Liu et al. (71), 2014 | Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis | Yes | | Didn't include quality assessment |
| 72. | 1945 | Liu et al. (72), 2016 | Meta-analysis of the correlation between the TNF-alpha308G/A polymorphism and polycystic ovary syndrome | Yes | | Didn't include quality assessment |
| 73. | 2181 | Liu et al. (73), 2017 | Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. | Yes | | Didn't include quality assessment |
| 74. | 1385 | Louwers et al. (74), 2013 | Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome | Yes | | Didn't include quality assessment or number of articles extracted on search |

Appendix 2: Continued

| | | | | | | |
|-----|------|---|---|-----|---------------------------------|---|
| 75. | 1956 | Mancini et al. (75), 2011 | Gonadotrophin-releasing hormone-antagonists vs long agonist in in-vitro fertilization patients with polycystic ovary syndrome: a meta-analysis | Yes | Fertility treatment | Didn't include quality assessment |
| 76. | 1966 | Misso et al. (76), 2012 | Status of clomiphene citrate and metformin for infertility in PCOS | Yes | | Not an original systematic review or meta-analysis |
| 77. | 1965 | Misso and <i>Teede</i> (77), 2015 | Metformin in women with PCOS, cons | Yes | | Not an original systematic review or meta-analysis |
| 78. | 1978 | Morris et al. (78), 2016 | What does a diagnostic label of 'polycystic ovary syndrome' really mean in adolescence? A review of current practice recommendations | Yes | Assessment | Didn't include quality assessment |
| 79. | 1985 | Naderpoor et al. (79), 2016 | Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis | Yes | | Didn't include search terms |
| 80. | 1642 | Nahuis et al. (80), 2011 | Metformin co-administration during follicle stimulating hormone ovulation induction with timed intercourse or intra-uterine insemination for subfertility associated with polycystic ovary syndrome | Yes | Protocol only, no review | Protocol only |
| 81. | 1986 | Nahuis et al. (81), 2013 | The basic fertility workup in women with polycystic ovary syndrome: a systematic review | Yes | Assessment | Didn't include quality assessment |
| 82. | 1988 | Niafar et al. (82), 2016 | A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries | Yes | | Didn't include quality assessment |
| 83. | 1990 | Nicholson et al. (83), 2010 | Effectiveness of long-term (twelve months) nonsurgical weight loss interventions for obese women with polycystic ovary syndrome: a systematic review | Yes | Lifestyle treatment | Didn't include quality assessment |
| 84. | 1335 | Palomba et al. (84), 2015 | Pregnancy complications in women with polycystic ovary syndrome | Yes | Assessment | Didn't include number of articles extracted on search or quality assessment |
| 85. | 1407 | Parsanezhad et al. (85), 2009 | Surgical ovulation induction in women with polycystic ovary syndrome: a systematic review | Yes | Fertility treatment | Didn't include number of articles extracted on search or quality assessment |
| 86. | 2187 | Paul et al. (86), 2016 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-art and future perspectives. | Yes | | Not an original systematic review or meta-analysis |
| 87. | 2012 | Peitsidis and <i>Agrawal</i> (87), 2010 | Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review | Yes | Assessment | Didn't include quality assessment |
| 88. | 2013 | Peng et al. (88), 2014 | The association between androgen receptor gene CAG polymorphism and polycystic ovary syndrome: a case-control study and meta-analysis | Yes | | Didn't include quality assessment |
| 89. | 2023 | Qin et al. (89), 2013 | Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis | Yes | Assessment | Didn't include quality assessment |
| 90. | 2025 | Rajender et al. (90), 2013 | Androgen receptor CAG repeats length polymorphism and the risk of polycystic ovarian syndrome (PCOS) | Yes | | Didn't include quality assessment |
| 91. | 2183 | Reis et al. (91), 2017 | Vitamin D receptor polymorphisms and the polycystic ovary syndrome: A systematic review. | Yes | | Not an original systematic review or meta-analysis |
| 92. | 2031 | Ren et al. (92), 2014 | [A meta-analysis on acupuncture treatment of polycystic ovary syndrome] | Yes | Complementary therapy | Not in English |
| 93. | 2036 | Rocca et al. (93), 2015 | Polycystic ovary syndrome: chemical pharmacotherapy | Yes | | Not a systematic review |
| 94. | 2041 | Saha et al. (94), 2013 | N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: A review of reported outcomes | Yes | Non-fertility medical treatment | Didn't include quality assessment |

Appendix 2: Continued

| | | | | | | |
|------|------|---|---|-----|---|--|
| 95. | 2044 | San-Millan and <i>Escobar-Morreale</i> (95), 2010 | The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence | Yes | | Didn't include quality assessment |
| 96. | 1663 | Showell et al. (96), 2016 | Inositol for subfertile women with polycystic ovary syndrome | Yes | Protocol only, no review | Protocol only |
| 97. | 2073 | Sirmans et al. (97), 2012 | Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications | Yes | | Didn't include number of articles extracted on search or quality assessment |
| 98. | 2080 | Song et al. (98), 2014 | Lack of association of INS VNTR polymorphism with polycystic ovary syndrome: a meta-analysis | Yes | | Didn't include quality assessment |
| 99. | 2087 | Sun et al. (99), 2013 | Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials | Yes | Fertility treatment | Didn't include quality assessment |
| 100. | 2090 | Taghavi et al. (100), 2015 | Health-related quality of life in polycystic ovary syndrome patients: A systematic review | Yes | | Not primarily focused on PCOS |
| 101. | 2097 | Tang et al. (101), 2009 | WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome | Yes | Fertility treatment/ Non-fertility medical treatment | Withdrawn from publication as error in citation |
| 102. | 1673 | Tang et al. (102), 2010 | Ultrasound-guided transvaginal ovarian needle drilling for clomiphene-resistant polycystic ovarian syndrome in subfertile women | Yes | Protocol only, no review | Protocol only |
| 103. | 2095 | Tang et al. (103), 2012 | Association of Pro12A1a polymorphism in peroxisome proliferator-activated receptor gamma with polycystic ovary syndrome: a meta-analysis | Yes | | Didn't include quality assessment |
| 104. | 2101 | Tang et al. (104), 2015 | Insulin receptor substrate-1 (IRS-1) rs1801278G>A polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis | Yes | | Didn't include quality assessment |
| 105. | 2184 | Tang et al. (105), 2017 | Circulating omentin-1 levels in women with polycystic ovary syndrome: a meta-analysis. | Yes | | Didn't include quality assessment |
| 106. | 2103 | Thethi et al. (106), 2015 | Role of Insulin Sensitizers on Cardiovascular Risk Factors in Polycystic Ovarian Syndrome: A Meta-Analysis | Yes | | "Reviewers worked independently and in duplicate to determine the methodological quality" but no details given |
| 107. | 1406 | Tomlinson et al (107), 2010 | Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? | Yes | | Didn't include search terms or number of articles extracted on search |
| 108. | 2110 | Toulis et al. (108), 2011 | Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome | Yes | Assessment | Didn't include quality assessment |
| 109. | 2111 | Tsikouras et al. (109), 2015 | Features of Polycystic Ovary Syndrome in adolescence | Yes | Assessment | Didn't include number of articles extracted on search or quality assessment |
| 110. | 2116 | Unfer et al. (110), 2012 | Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials | Yes | Non-fertility medical treatment | Didn't include quality assessment |
| 111. | 2134 | Wang et al. (111), 2012 | [Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis] | Yes | Fertility treatment | Not in English |
| 112. | 2136 | Wang et al. (112), 2012 | Negative association between androgen receptor gene CAG repeat polymorphism and polycystic ovary syndrome? A systematic review and meta-analysis | Yes | | Didn't include quality assessment |

Appendix 2: Continued

| | | | | | | |
|------|------|--------------------------------------|--|-----|---------------------------------|---|
| 113. | 2132 | Wang et al. (113), 2015 | 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with polycystic ovary syndrome in Chinese patients: a meta-analysis | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 114. | | Wang et al. (114), 2016 | Clomiphene, metformin, letrozole, tamoxifen or combined clomiphene-metformin for polycystic ovary syndrome - a systematic review and individual participant data network meta-analysis. | Yes | | Conference abstract only, no related publication found No available online reference |
| 115. | 2146 | Wild et al. (115), 2010 | Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society | Yes | | Not a systematic review |
| 116. | 2147 | Wild et al. (116), 2011 | Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis | Yes | Assessment | Didn't include quality assessment |
| 117. | 2148 | Wojciechowski et al. (117), 2012 | Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis | Yes | | Didn't include quality assessment |
| 118. | 2151 | Wu et al. (118), 2016 | Acupuncture for treating polycystic ovary syndrome: guidance for future randomized controlled trials | Yes | Complementary therapy | Didn't include number of articles extracted on search |
| 119. | 2152 | Xian et al. (119), 2012 | ADIPOQ gene polymorphisms and susceptibility to polycystic ovary syndrome: a HuGE survey and meta-analysis | Yes | | Didn't include quality assessment |
| 120. | 1322 | Xian et al. (120), 2016 | Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis | Yes | | Didn't include quality assessment |
| 121. | 2155 | Xie et al. (121), 2013 | Microsatellite polymorphism in the fibrillin 3 gene and susceptibility to PCOS: a case-control study and meta-analysis | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 122. | 2156 | Xu et al. (122), 2014 ¹²⁰ | Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review | Yes | Non-fertility medical treatment | Didn't include quality assessment |
| 123. | 2159 | Yu et al. (123), 2014 | Polymorphisms of pentanucleotide repeats (tttta)n in the promoter of CYP11A1 and their relationships to polycystic ovary syndrome (PCOS) risk: a meta-analysis | Yes | | Didn't include quality assessment |
| 124. | 2185 | Yu et al. (124), 2017 | Comparative effectiveness of 9 ovulation-induction therapies in patients with clomiphene citrate-resistant polycystic ovary syndrome: a network meta-analysis | Yes | | Didn't include search terms |
| 125. | 2163 | Zhang et al. (125), 2012 | Association between the Pro12Ala polymorphism of PPAR-gamma gene and the polycystic ovary syndrome: a meta-analysis of case-control studies | Yes | | Didn't include quality assessment |
| 126. | 2168 | Zhang et al. (126), 2014 | The -675 4G/5G polymorphism in the PAI-1 gene may not contribute to the risk of PCOS | Yes | | Didn't include quality assessment or number of articles extracted on search |
| 127. | 2166 | Zhang et al. (127), 2015 | Peroxisome proliferator-activated receptor gamma rs1801282 C>G polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis involving 7,069 subjects | Yes | | Didn't include quality assessment |
| 128. | 2171 | Zheng et al. (128), 2013 | The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials | Yes | Non-fertility medical treatment | Didn't include quality assessment |

Appendix 3: Characteristics of included reviews

| Author and year | Country | Date assessed as up to date | Included studies | Study type | Language | Meta-analysis performed | Included studies quality | Systematic review guidelines followed | Population | PCOS diagnostic criteria | Participant number | Intervention | Comparison |
|--------------------------------|--|-----------------------------|------------------|--|---------------|-------------------------|--------------------------|---------------------------------------|--|---|--------------------|--|---|
| Abu Hashim et al. (129), 2015 | Egypt | Feb-15 | 12 | RCT | Only English | Yes | Unclear | Yes | CC resistant PCOS | ESHRE/ASRM | 1411 | CC and metformin | Gns, LOD, AIs, NAC and other insulin sensitizers+CC |
| Al Khalifah et al. (130), 2016 | Canada, Saudi Arabia, Colombia, UK | Jan-15 | 4 | RCT | All languages | Yes | Low to very low quality | Yes | adolescents with PCOS (11-19 year old) | ESHRE/ASRM | 231 | Metformin (include con-intervention with pioglitazone, spironolactone, flutamide or lifestyle) | Oral contraceptive pills |
| Baghdadi et al. (131), 2012 | Australia, Saudi Arabia, Egypt, UK, Italy, UAE, Austria, China, France | Sep-11 | 15 | Not stated | All languages | Yes | Unclear | No | CC resistant PCOS | ESHRE/ASRM | 1784 | OAT in lean patients | OAT in overweight and obese patients |
| Bordewijk et al. (132), 2017 | Netherlands, Australia, Brazil | Jun-16 | 5 | RCT and phase one in cross-over trials | All languages | Yes | Unclear | Yes | PCOS and anovulatory women | ESHRE/ASRM | 264 | FSH+metformin | FSH |
| Brown and Farquhar (133), 2017 | New Zealand | Aug-16 | 28 | RCT and phase one in cross-over trials | All languages | Yes | No | Yes | WHO group 2 anovulation | WHO classification of anovulation | 3377 | Antioestrogen± medical therapy, CC regimen A | Placebo, Antioestrogen± medical therapy, CC regimen B |
| Butterworth et al. (134), 2016 | UK | Mar-15 | 6 | Epidemiological studies | Not stated | No | No | Yes | PCOS before bariatric surgery | No specified criteria | 264 | Before bariatric surgery | After bariatric surgery |
| Ding et al. (135), 2016 | China | Not stated | 4 | RCT | All languages | Yes | No | Yes | PCOS | ESHRE/ASRM | 704 | CC in luteal phase | CC in follicular phase |
| Fang et al. (136), 2017 | China | Dec-15 | 9 | RCT | English | Yes | Yes | No | PCOS | ESHRE/ASRM | 502 | Vitamin D | Placebo or Metformin |
| Farquhar et al. (137), 2012 | New Zealand | May-12 | 25 | RCT | All languages | Yes | Low-moderate | Yes | CC resistant PCOS | Clinical features, abnormal endocrine tests, ultrasonographic or visual appearance of ovaries | 2304 | LOD with or without OI LOD in women undergoing ART LOD techniques | Other medical treatment, Without LOD Various technique of LOD |

Appendix 3: Continued

| | China | Oct-14 | 5 | Randomised and non-randomised control trials, total participants not <30 | English | Yes | Unclear | No | PCOS, pregnant and took metformin to get conception | ESHRE/ASRM | 929 | Metformin throughout pregnancy | Placebo |
|----------------------------|--------------------------|------------|----|--|---------------|-----|--------------------------------|-----|---|-----------------------|-----------------------|--|--|
| Feng et al. (138), 2015 | China | Oct-14 | 5 | Randomised and non-randomised control trials, total participants not <30 | English | Yes | Unclear | No | PCOS, pregnant and took metformin to get conception | ESHRE/ASRM | 929 | Metformin throughout pregnancy | Placebo |
| Frank et al. (139), 2014 | Netherlands, New Zealand | Sep-14 | 26 | RCT and phase one in cross-over trials | All languages | Yes | Low | Yes | PCOS, reproductive age | ESHRE/ASRM | 5560 | AIs (alone or in conjunction with medical adjuncts) by sexual intercourse | AIs compared to each other and to other treatments |
| | Scotland | May-13 | 4 | RCT | Only English | No | 3 high quality, 1 poor quality | No | CC resistant PCOS, reproductive age | No specified criteria | 129 | Metformin | Placebo ± CC |
| Graff et al. (141), 2016 | Brazil | May-15 | 9 | prospective studies and RCT | All languages | Yes | Unclear | No | PCOS | ESHRE/ASRM | 602 | Orlistat for at least 8 weeks | Placebo Metformin Anti-obesity drugs CC |
| He and Jiang (142), 2011 | China | Jun-10 | 6 | RCT | All languages | Yes | Unclear | No | PCOS | ESHRE/ASRM | 841 | Letrozole | CC |
| Huang et al. (143), 2015 | USA, China | Dec-13 | 12 | RCT | Only English | Yes | Unclear | No | PCOS undergoing IVF/ICSI in non-donor cycles | ESHRE/ASRM | 1731 | Metformin | Placebo |
| Kollman et al. (144), 2016 | Austria, UK, Brazil | Jul-15 | 66 | RCT | English | Yes | Yes | No | PCOS | No specified criteria | 6377 | Any interventions aimed at improving the effectiveness of or reducing complications of ART | Not applicable |
| Li et al. (145), 2011 | China | May-10 | 10 | RCT | Only English | Yes | Unclear | No | PCOS | No specified criteria | 459 | Metformin | Thiazolidinediones |
| Luo et al. (146), 2014 | China | Not stated | 2 | Not stated | Only English | Yes | Unclear | No | PCOS undergoing COS/IUI | No specified criteria | Only n. of cycles 333 | GNRH antagonist+IUI | IUI |
| Misso et al. (147), 2012 | Australia | Jul-11 | 13 | RCT, SR of RCT | Only English | Yes | Low-high | No | PCOS | ESHRE/ASRM | 2059 | AIs | Placebo, no other treatment or other infertility treatment including AIs in combination with other treatment |

Appendix 3: Continued

| Author | Country | Date | n | Design | Language | Yes | Low-Moderate | No | PCOS | ESHRE/ASRM | n | At least 1000 mg of any type of metformin at any frequency including slow release and standard release | Any type, dose and frequency of CC |
|----------------------------|------------------|------------------------|----|-------------------------------------|---------------|-----|----------------------------|-----|--|--|-----------------------------|--|--|
| Missou et al. (148), 2013 | Australia | Jul-11 | 4 | RCT, SR of RCT | Only English | Yes | Low-Moderate | No | PCOS | ESHRE/ASRM | 457 | At least 1000 mg of any type of metformin at any frequency including slow release and standard release | Any type, dose and frequency of CC |
| Moazami et al. (149), 2014 | Iran | Unclear, no time limit | 6 | RCT | Not stated | Yes | Unclear | Yes | CC-resistant PCOS | No specified criteria | 499 | LOD | Gns |
| Palomba et al. (150), 2009 | Italy, USA | Mar-08 | 4 | RCT | All languages | Yes | Unclear | No | PCOS | ESHRE/ASRM | 1066 | CC CC + metformin CC + metformin | Metformin CC metformin |
| Palomba et al. (151), 2009 | Italy | Jun-08 | 17 | RCT | All languages | Yes | Unclear | Yes | PCOS | ESHRE/ASRM or any non-validated criteria | 1741 | Pregestational metformin | Unclear |
| Palomba et al. (152), 2013 | Italy | Aug-12 | 10 | RCT and phase one cross over trials | All languages | Yes | Unclear | Yes | PCOS undergoing IVF cycles | No specified criteria | 845 | Metformin+Gns | No treatment/ placebo+ Gns |
| Palomba et al. (153), 2014 | Italy | Oct-13 | 7 | RCT and phase one cross over trials | All languages | Yes | Low | Yes | PCOS | No specified criteria | 1023 cycles in 334 patients | Metformin | Placebo/no treatment |
| Pundir et al. (154), 2012 | UK | Aug-10 | 9 | RCT | All languages | Yes | Unclear | No | PCOS undergoing IVF with or without ICSI | No specified criteria | 966 | GNRH antagonist | GNRH agonist |
| Pundir et al. (155), 2017 | UK, Australia | Aug-16 | 10 | RCT | All languages | Yes | No | No | PCOS | No specified criteria | 601 | Inositol | Placebo Metformin Clomiphene Another isomeric form of inositol Placebo Other drugs |
| Raval et al. (156), 2011 | India, Australia | Jul-11 | 4 | RCT and phase one cross over trials | All languages | Yes | Unclear | Yes | PCOS (not trying to conceive) | ESHRE/ASRM | 244 | Statins ± other drugs | Placebo Other drugs |
| Roque et al. (157), 2015 | Brazil | Oct-14 | 7 | RCT | Only English | Yes | Unclear | Yes | PCOS (therapy naive) | ESHRE/ASRM | 1833 | Letrozole | CC |
| Siebert et al. (158), 2012 | South Africa | Nov-10 | 14 | RCT | All languages | Yes | Unclear | No | PCOS (therapy naive) | ESHRE/ASRM | 2240 | Metformin (500-2000 mg/day) | CC (CC max. 200 mg/day) or CC+Metformin |
| Sinawat et al. (159), 2012 | Thailand | Feb-12 | 0 | RCT | All languages | No | No studies were identified | Yes | PCOS and of reproductive age | ESHRE/ASRM | 0 | Short-course (less than four weeks) metformin + CC | Long-course (four weeks or more) metformin + CC. |

Appendix 3: Continued

| Author(s) | Country | Date | Study Design | Language | No. of studies identified | PCOS | ESHRE/ASRM | Number of patients | Intervention | Control |
|---------------------------------|------------------------|--------|--------------|---------------|----------------------------|--|---|---|--|--|
| Siristatidis et al. (160), 2013 | Greece, UK | May-13 | 0 | All languages | No studies were identified | PCOS | 0 | | IVM followed by IVF or ICSI. Embryo transfers of both fresh and frozen but not mixed embryos | Conventional IVF or ICSI after controlled ovarian hyper-stimulation |
| Siristatidis et al. (161), 2015 | Greece | Oct-13 | 11 | All languages | Unclear | PCOS, PCO and control undergoing IVM | PCOS (according to the criteria that each study adopted), PCO (ultrasonographic appearance of polycystic ovaries, as a rule) and controls (sub-fertile patients with other causes of sub-fertility, such as tubal or male factor) | 808 (268 PCOS patients (328 cycles), 100 PCO patients (110 cycles) and 440 controls (480 cycles)) | IVM in PCOS | IVM in PCO/control |
| Tang et al. (162), 2012 | UK, Australia | Oct-11 | 44 | All languages | Low | PCOS | ESHRE/ASRM | 3992 | Metformin, rosiglitazone or pioglitazone± ovulation induction agent | Placebo, no treatment or ovulation induction agent, CC |
| Thakker et al. (163), 2015 | India, Usa | Sep-13 | 8 | All languages | Unclear | PCOS | ESHRE/ASRM | 910 | NAC ± other agent | Placebo± other agent |
| Tso et al. (164), 2014 | Brazil, Australia | Oct-14 | 9 | All languages | Low-moderate | PCOS and of reproductive age undergoing IVF or ICSI | ESHRE/ASRM (Rotterdam criteria) | 816 | Metformin before or during IVF or ICSI treatment. | No treatment or placebo |
| Weiss et al. (165), 2015 | Netherlands, Australia | Oct-14 | 14 | All languages | Very low-low | CC-resistant ± failure PCOS Women treated in the past by metformin with or without CC Women with prior treatment with electrocautery of the ovaries. | No specified criteria | 1726 | OI with rFSH or FSH-HP, HMG, HP-HMG (IUI could be included) | OI with HMG, FSH-P, FSH-HP or FSH-P or FSH-P, FSH-HP (IUI could be included) |

Appendix 3: Continued

| | China | Jun-11 | 8 | RCT | English and Chinese | Yes | Little possibilities of bias -2, moderate bias-5, high possibilities of bias -1 | No | PCOS, <35 years | ESHRE/ASRM | 1487 | Metformin±CC | CC |
|-----------------------------|------------|--------|----|-------------------------------------|---------------------|-----|---|-----|-------------------|---------------|------|---|--|
| Xiao et al. (166), 2012 | China | Dec-11 | 7 | RCT | English and Chinese | Yes | Insufficient quality | No | PCOS | ESHRE/ASRM | 755 | GNRH antagonist | GNRH agonist |
| Xingrong et al. (168), 2016 | China, USA | Jul-13 | 11 | not stated | All languages | Yes | Unclear | Yes | PCOS and pregnant | Not specified | 1496 | Metformin throughout pregnancy | No metformin during pregnancy |
| Zeng et al. (169), 2016 | China | Sep-15 | 13 | Any study with a control group | All languages | Yes | Unclear | No | PCOS and pregnant | ESHRE/ASRM | 1606 | Metformin at least 1 trimester | Placebo |
| Zhang et al. (170), 2014 | China | Sep-13 | 6 | RCT | English | Yes | Poor quality | No | PCOS | ESHRE/ASRM | 263 | Acarbose± ovulation inducing agent | Placebo, metformin |
| Zhuang et al. (171), 2013 | China | Jun-12 | 1 | RCT and phase one cross over trials | All language | No | Limited quality | Yes | PCOS | ESHRE/ASRM | 16 | Antidepressants (either alone, or in combination with other drug) | Placebo Oral contraceptive pills Metformin Lifestyle Antiobesity drugs Surgery Another antidepressant Different doses of the same antidepressant |
| Zhuo et al. (172) 2014 | China | Dec-13 | 13 | Any study with a control group | All languages | Yes | Unclear | No | PCOS and pregnant | ESHRE/ASRM | 1828 | Metformin throughout pregnancy | Placebo |

AI: Aromatase inhibitors, CC: Clomiphene citrate, COS; Controlled ovarian stimulation, ESHRE/ASRM; European society of human reproduction and embryology/American society for reproductive medicine, FSH: Follicle stimulating hormone, FSH-HP: Follicle stimulating hormone-highly purified, FSH-P: Follicle stimulating hormone-purified, GDM: Gestational diabetes mellitus, Gns; Gonadotrophins, HCG; Human chorionic gonadotrophin, HMG; Human menopausal gonadotrophin, HP-HMG: Highly purified human menopausal gonadotrophin, ICSI; Intra cytoplasmic sperm injection, IUGR; Intra-uterine growth restriction, IUI; Intra uterine insemination, IVF; In vitro fertilization, IVM; In vitro maturation, LOD; Laparoscopic ovarian drilling, NAC; N-acetyl cysteine, OAT; Ovarian ablation therapy, OHSS; Ovarian hyper-stimulation syndrome, OI; Ovulation induction, PCO; Polycystic ovary, PCOS; Polycystic ovary syndrome, PIH/PE; Pregnancy induced hypertension/Preeclampsia, RCT; Randomized control trial, rFSH; Recombinant follicle stimulating hormone, SR; Systematic review, uFSH; Urinary follicle stimulating hormone, and WHO; World Health Organization.

Appendix 4: Assessment of methodological quality of included reviews

| | 1 Pre-specified questions and inclusion criteria | 2 Duplicate study selection and data extraction | 3 Comprehensive literature search | 4 Grey literature included | 5 Lists included and excluded studies | 6 Characteristics of included studied | 7 Study quality assessed | 8 Quality assessments in conclusion | 9 Assessment of homogeneity | 10 Assessment of publication bias | 11 Conflict of interest | AMSTAR Score | Quality |
|---------------------------------|--|---|---|-------------------------------|---|---|-----------------------------|---|-----------------------------------|---|----------------------------|-----------------|----------|
| Abu Hashim et al. (129), 2015 | No | Yes | No | No | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 | Moderate |
| Al Khalifah et al. (130), 2016 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | No | 9 | High |
| Baghdadi et al. (131), 2012 | No | No | No | No | No | Yes | Yes | No | Yes | Yes | No | 4 | Moderate |
| Bordewijk et al. (132), 2017 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | 9 | High |
| Brown and Farquhar (133), 2017 | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 9 | High |
| Butterworth et al. (134), 2016 | No | No | No | No | No | Yes | No | No | N/A | No | No | 1 | Low |
| Ding et al. (135), 2016 | No | No | No | No | No | Yes | No | No | Yes | No | No | 2 | Low |
| Fang et al. (136), 2017 | No | Yes | No | No | No | Yes | Yes | No | Yes | Yes | No | 5 | Moderate |
| Farquhar et al. (137), 2012 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | 9 | High |
| Feng et al. (138), 2015 | No | No | No | No | No | Yes | No | No | Yes | Yes | No | 3 | Low |
| Franik et al. (139),2014 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 10 | High |
| Dissemination (140) | Yes | No | No | No | No | Yes | Yes | N/A | N/A | N/A | No | 3 | Low |
| Graff et al. (141) 2016 | Yes | Yes | No | No | No | Yes | No | No | Yes | Yes | No | 5 | Moderate |
| He and Jiang (142), 2011 | No | No | No | No | No | Yes | Yes | Yes | Yes | No | No | 4 | Moderate |
| Huang et al. (143)2015 | No | Yes | Yes | No | No | Yes | Yes | Yes | Yes | No | No | 6 | Moderate |
| Kollman et al. (144), 2016 | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | No | 8 | High |
| Li et al. (145), 2011 | No | No | No | No | No | Yes | Yes | Yes | Yes | No | No | 4 | Moderate |
| Luo et al. (146), 2014 | No | Yes | No | No | Yes | Yes | Yes | Yes | Yes | No | No | 6 | Moderate |
| Misso et al. (147), 2012 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | 8 | High |
| Misso et al. (148), 2013 | Yes | No | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | 8 | High |
| Moazami et al. (149), 2014 | No | Yes | No | No | Yes | Yes | Yes | No | Yes | No | No | 5 | Moderate |
| Palomba et al. (150), 2009 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | 7 | Moderate |
| Palomba et al (151), 2009 | No | No | Yes | No | Yes | Yes | Yes | Yes | Yes | No | No | 6 | Moderate |
| Palomba et al. (152), 2013 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | No | No | 7 | Moderate |
| Palomba et al. (153), 2014 | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes | No | No | 7 | Moderate |
| Pundir et al. (154), 2012 | No | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | No | No | 7 | Moderate |
| Pundir et al. (155), 2017 | No | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | 7 | Moderate |
| Raval et al. (156), 2011 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 10 | High |
| Roque et al. (157), 2015 | No | Yes | No | No | Yes | Yes | Yes | No | Yes | No | No | 5 | Moderate |
| Siebert et al. (158), 2012 | No | No | Yes | No | No | Yes | No | No | Yes | No | No | 3 | Low |
| Sinawat et al. (159), 2012 | Yes | No | Yes | Yes | Yes | N/A | Yes | N/A | N/A | Yes | Yes | 7 | Moderate |
| Siristatidis et al. (160), 2013 | Yes | Yes | Yes | Yes | Yes | N/A | Yes | N/A | N/A | Yes | Yes | 8 | High |
| Siristatidis et al. (161), 2015 | No | Yes | No | No | Yes | Yes | Yes | No | Yes | Yes | No | 6 | Moderate |
| Tang et al. (162), 2012 | Yes | No | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | 8 | High |
| Thakker et al. (163), 2015 | Yes | No | Yes | Yes | No | Yes | Yes | Yes | No | Yes | Yes | 8 | High |
| Tso et al (164), 2014 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | No | 9 | High |
| Weiss et al. (165), 2015 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 10 | High |
| Xiao et al. (166), 2012 | No | No | Yes | No | No | No | Yes | No | Yes | No | No | 3 | Low |
| Xiao et al. (167), 2013 | No | No | Yes | No | No | No | Yes | Yes | Yes | No | No | 4 | Moderate |
| Xingrong et al. (168), 2016 | No | No | No | No | No | Yes | No | No | Yes | Yes | No | 3 | Low |
| Zeng et al. (169), 2016 | No | No | Yes | Yes | No | Yes | No | No | Yes | Yes | No | 5 | Moderate |
| Zhang et al. (170), 2014 | No | No | No | No | No | Yes | Yes | Yes | Yes | Yes | No | 5 | Moderate |
| Zhuang et al. (171), 2013 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | N/a | Yes | No | 8 | High |
| Zhuo et al. (172), 2014 | No | No | Yes | Yes | No | Yes | Yes | No | Yes | No | No | 5 | Moderate |

References

1. Abu Hashim H. Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence? *Reprod Biomed Online*. 2016; 32(1): 44-53.
2. Al Khalifah RA, Florez ID, Dennis B, Neupane B, Thabane L, Bassilious E. The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. *Syst*. 2015; 4: 125.
3. Al-Khalifah RA, Florez ID, Dennis B. The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis. *Endocrine reviews: Conference: 98th annual meeting and expo of the endocrine society*. 2016; ENDO 37.
4. Andrade C. Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy. *J Clin Psychiatry*. 2016; 77(4): e411-e414.
5. Atiomo W, Khalid S, Parameshwaran S, Houda M, Layfield R. Proteomic biomarkers for the diagnosis and risk stratification of polycystic ovary syndrome: a systematic review. *Bjog*. 2009; 116(2): 137-143.
6. Bagos PG. Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. *Mol Hum Reprod*. 2009; 15(1): 19-26.
7. Bao S, Cai JH, Yang SY, Ren Y, Feng T, Jin T, et al. Association of DENND1A gene polymorphisms with polycystic ovary syndrome: a meta-analysis. *J Clin Res Pediatr Endocrinol*. 2016; 8(2): 135-143.
8. Baranova A, Tran TP, Biredinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2011; 33(7): 801-814.
9. Barba M, Schunemann HJ, Sperati F, Akl EA, Musicco F, Guyatt G, et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. 2009; 70(5): 661-670.
10. Bayram N, van Wely M, Van der Veen F. Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome. *Cochrane Database Syst Rev*. 2010; (11).
11. Birch Petersen K, Pedersen NG, Pedersen AT, Lauritsen MP, la Cour Freiesleben N. Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction. *Reprod Biomed Online*. 2016; 32(6): 563-583.
12. Bouza-Alvarez C, Ruiz-Lopez M, Alcazar-Alcazar R, Lopez-Cuadrado T. Safety and efficacy of metformin in improving clinical, hormonal and metabolic features of polycystic ovary syndrome. *Systematic review and meta-analysis Madrid*. Agencia de Evaluacion de Tecnologias Sanitarias (AETS). 2011.
13. Bronstein J, Tawdekar S, Liu Y, Pawelczak M, David R, Shah B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. *J Pediatr Adolesc Gynecol*. 2011; 24(1): 15-20.
14. Cahill D. Pcos. *Clin Evid (Online)*. 2009.
15. Cahill DJ, O'Brien K. Polycystic ovary syndrome (PCOS): metformin. *Clin Evid (Online)*. 2015.
16. Cai X, Liu C, Mou S. Association between fat mass- and obesity-associated (FTO) gene polymorphism and polycystic ovary syndrome: a meta-analysis. *PLoS One*. 2014; 9(1): e86972.
17. Carlus SJ, Sarkar S, Bansal SK, Singh V, Singh K, Jha RK, et al. Is MTHFR 677 C>T polymorphism clinically important in polycystic ovarian syndrome (PCOS)? A case-control study, meta-analysis and trial sequential analysis. *PLoS One*. 2016; 11(3): e0151510.
18. Chen DJ, Ding R, Cao JY, Zhai JX, Zhang JX, Ye DQ. Two follicle-stimulating hormone receptor polymorphisms and polycystic ovary syndrome risk: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2014; 182: 27-32.
19. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. *Reprod Biomed Online*. 2009; 19(3): 398-405.
20. Conte F, Banting L, Teede H, Stepto N. Mental health and physical activity in women with polycystic ovary syndrome: a brief review. *Sports Medicine*. 2015; 45(4): 497-504.
21. Costello MF, Shrestha B, Eden J, Johnson N, Moran LJ. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. *Cochrane Database Syst Rev*. 2010; (11).
22. Dissemination CfRa. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss (Provisional abstract). *DARE*. 2015; (2).
23. Dissemination CfRa. N-acetylcysteine for treating women with clomiphene citrate resistant polycystic ovary syndrome: a systematic review (Provisional abstract). *DARE*. 2015; (2).
24. Dissemination CfRa. Rosiglitazone versus metformin for polycystic ovary syndrome: a systematic review (Provisional abstract). *DARE*. 2015; (2).
25. Dissemination CfRa. Efficacy of inositol in women with polycystic ovary syndrome and desire for children: systematic review and meta-analysis (Provisional abstract). *DARE*. 2015; (2).
26. Dissemination CfRa. Letrozole for ovulation induction in women with polycystic ovarian syndrome: a systematic analysis (Provisional abstract). *DARE*. 2015; (2).
27. Dissemination CfRa. Thiazolidinediones combined with metformin in treatment of polycystic ovary syndrome: a systematic review (Provisional abstract). *DARE*. 2015; (2).
28. Dissemination CfRa. Laparoscopic surgery versus laparotomy for women with polycystic ovarian syndrome: a systematic review (Provisional abstract). *DARE*. 2015; (2).
29. Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Obstet Gynecol*. 2011; 117(1): 145-152.
30. Du J, Zhang W, Guo L, Zhang Z, Shi H, Wang J, et al. Two FSHR variants, haplotypes and meta-analysis in Chinese women with premature ovarian failure and polycystic ovary syndrome. *Mol Genet Metab*. 2010; 100(3): 292-295.
31. Du D, Li X. The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis. *Int J Clin Exp Med*. 2013; 6(10): 880-889.
32. Eckmann KR, Kockler DR. Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome. *Ann Pharmacother*. 2009; 43(7): 1338-1346.
33. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. *Fertil Steril*. 2011; 95(3): 1048-58. e1-e2.
34. Escobar-Morreale HF, Roldán-Martín MB. Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis. *Diabetes Care*. 2016; 39(4): 639-648.
35. Eyvazzadeh AD, Pennington KP, Pop-Busui R, Sowers M, Zubieta JK, Smith YR. The role of the endogenous opioid system in polycystic ovary syndrome. *Fertil Steril*. 2009; 92(1): 1-12.
36. Fan W, Li S, Chen Q, Huang Z. Association between the (TAAA)n SHBG polymorphism and PCOS: a systematic review and meta-analysis. *Gynecol Endocrinol*. 2013; 29(7): 645-650.
37. Farquhar C, Ying T, Wu T. Laparoscopic ovarian diathermy versus metformin for women with polycystic ovarian syndrome. *Cochrane Database Syst Rev*. 2009; (4).
38. Fernandez H, Morin-Surruca M, Torre A, Faivre E, Deffieux X, Ger-vaise A. Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review. *Reprod Biomed Online*. 2011; 22(6): 556-568.
39. Frary JM, Bjerre KP, Glintborg D, Ravn P. The effect of dietary carbohydrates in women with polycystic ovary syndrome: a systematic review. *Minerva Endocrinol*. 2016; 41(1): 57-69.
40. Fu LY, Dai LM, Li XG, Zhang K, Bai Y. Association of methylenetetrahydrofolate reductase gene C677T polymorphism with polycystic ovary syndrome risk: a systematic review and meta-analysis update. *Eur J Obstet Gynecol Reprod Biol*. 2014; 172: 56-61.
41. Galazis N, Olaleye O, Haoula Z, Layfield R, Atiomo W. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration. *Fertil Steril*. 2012; 98(6): 1590-1601. e1.
42. Galazis N, Iacovou C, Haoula Z, Atiomo W. Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol*. 2012; 160(2): 121-130.
43. Galazis N, Pang YL, Galazi M, Haoula Z, Layfield R, Atiomo W. Proteomic biomarkers of endometrial cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration. *Gynecol Endocrinol*. 2013; 29(7): 638-644.
44. Galazis N, Docheva N, Nicolaidis KH, Atiomo W. Proteomic biomarkers of preterm birth risk in women with polycystic ovary syndrome (PCOS): a systematic review and biomarker database integration. *PLoS One*. 2013; 8(1): e53801.
45. Gao L, Zhang Y, Cui Y, Jiang Y, Wang X, Liu J. Association of the T45G and G276T polymorphisms in the adiponectin gene with

- PCOS: a meta-analysis. *Gynecol Endocrinol.* 2012; 28(2): 106-110.
46. Garg D, Merhi Z. Relationship between advanced glycation end products and steroidogenesis in PCOS. *Reprod Biol Endocrinol.* 2016; 14(1): 71.
 47. Genazzani AD. Inositol as putative integrative treatment for PCOS. *Reprod Biomed Online.* 2016; 33(6): 770-780.
 48. Groth SW. Adiponectin and polycystic ovary syndrome. *Biol Res Nurs.* 2010; 12(1): 62-72.
 49. Gu HF, Mou M, Liang ZG, Sun C, Ren XY, Xiao YB. The association between paraoxonase 1 gene polymorphisms and polycystic ovarian syndrome. *Mol Cell Biol (Noisy-le-Grand, France).* 2016; 62(14): 44-47.
 50. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. *Hum Reprod.* 2012; 27(5): 1327-1331.
 51. He J, Wang L, Liu J, Liu F, Li X. A meta-analysis on the association between PPAR-gamma Pro12Ala polymorphism and polycystic ovary syndrome. *J Assist Reprod Genet.* 2012; 29(7): 669-677.
 52. Huang M, Xiao J, Zhao X, Liu C, Chen Q. Four polymorphisms of the CAPN 10 gene and their relationship to polycystic ovary syndrome susceptibility: a meta-analysis. *Clin Endocrinol (Oxf).* 2012; 76(3): 431-438.
 53. Ioannidis A, Ikononi E, Dimou NL, Douma L, Bagos PG. Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a mendelian randomization meta-analysis. *Mol Genet Metab.* 2010; 99(2): 174-183.
 54. Jalilian A, Kiani F, Sayehmiri F, Sayehmiri K, Khodae Z, Akbari M. Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: a meta-analysis. *Iran J Reprod Med.* 2015; 13(10): 591-604.
 55. Janci MM, Smith RC, Odegard PS. Polycystic ovarian syndrome: metformin or thiazolidinediones for cardiovascular risk reduction? *Diabetes Spectr.* 2012; 25(4): 229-237.
 56. Jia H, Wang B, Yu L, Jiang Z. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with polycystic ovary syndrome: a meta-analysis. *J Renin Angiotensin Aldosterone Syst.* 2013; 14(3): 255-262.
 57. Jia J, Bai J, Liu Y, Yin J, Yang P, Yu S, et al. Association between retinol-binding protein 4 and polycystic ovary syndrome: a meta-analysis. *Endocr J.* 2014; 61(10): 995-1002.
 58. Johnson N. Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome—a meta-analysis of randomised trials. *Aust N Z J Obstet Gynaecol.* 2011; 51(2): 125-129.
 59. Kelly CJ, Stenton SR, Lashen H. Insulin-like growth factor binding protein-1 in PCOS: a systematic review and meta-analysis. *Hum Reprod Update.* 2011; 17(1): 4-16.
 60. Khan GH, Galazis N, Docheva N, Layfield R, Atiomo W. Overlap of proteomics biomarkers between women with pre-eclampsia and PCOS: a systematic review and biomarker database integration. *Hum Reprod.* 2015; 30(1): 133-148.
 61. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. *Am J Obstet Gynecol.* 2011; 204(6): 558. e1-6.
 62. Kong W, Niu X, Zeng T, Lu M, Chen L. Impact of treatment with metformin on adipocytokines in patients with polycystic ovary syndrome: a meta-analysis. *PLoS One.* 2015; 10(10): e0140565.
 63. Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. *Eur.* 2013; 169(6): 853-865.
 64. Lai L, Li X, Flower A, Moore M, Liu J. Chinese herbal medicine for oligomenorrhoea and amenorrhoea in polycystic ovary syndrome: a systematic review and meta-analysis. *J Altern Complement Med.* 2014; 20(5): A129-A.
 65. Lakkakula BV, Thangavelu M, Godla UR. Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review. *J Assist Reprod Genet.* 2013; 30(7): 883-895.
 66. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. *Metabolism.* 2013; 62(11): 1522-1534.
 67. Lee YH, Song GG. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol.* 2014; 175: 8-14.
 68. Lim CE, Wong WS. Current evidence of acupuncture on polycystic ovarian syndrome. *Gynecol Endocrinol.* 2010; 26(6): 473-478.
 69. Lin LH, Baracat MC, Maciel GA, Soares JM, Jr, Baracat EC. Androgen receptor gene polymorphism and polycystic ovary syndrome. *Int J Gynaecol Obstet.* 2013; 120(2): 115-118.
 70. Lin H, Li Y, Li L, Wang W, Yang D, Zhang Q. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. *PLoS One.* 2014; 9(3): e91796.
 71. Liu Y, Sun MG, Jiang R, Ding R, Che Z, Chen YY, et al. Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis. *J Assist Reprod Genet.* 2014; 31(3): 363-370.
 72. Liu XB, Deng XH, Zhou B, Zhang L, Niu XM. Meta-analysis of the correlation between the TNF-alpha308G/A polymorphism and polycystic ovary syndrome. *Genet Mol Res.* 2016; 15(2).
 73. Liu AL, Xie HJ, Xie HY, Liu J, Yin J, Hu JS, et al. Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. *BMC Med Genet.* 2017; 18(1): 89.
 74. Louwers YV, Stolk L, Uitterlinden AG, Laven JSE. Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2013; 98(12): E2006-E2012.
 75. Mancini F, Tur R, Martinez F, Coroleu B, Rodriguez I, Barri PN. Gonadotrophin-releasing hormone-antagonists vs long agonist in in-vitro fertilization patients with polycystic ovary syndrome: a meta-analysis. *Gynecol Endocrinol.* 2011; 27(3): 150-155.
 76. Misso ML, Teede HJ, Hart R, Wong J, Rombauts L, Melder AM, et al. Status of clomiphene citrate and metformin for infertility in PCOS. *Trends Endocrinol Metab.* 2012; 23(10): 533-543.
 77. Misso ML, Teede HJ. Metformin in women with PCOS, cons. *Endocrine.* 2015; 48(2): 428-433.
 78. Morris S, Grover S, Sabin MA. What does a diagnostic label of 'polycystic ovary syndrome' really mean in adolescence? A review of current practice recommendations. *Clin.* 2016; 6(1): 1-18.
 79. Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. *Hum Reprod Update.* 2015; 21(5): 560-574.
 80. Nahuis M, Costello MF, Van der Veen F, Tso LO, Oosterhuis J, Mol WB, et al. Metformin co-administration during follicle stimulating hormone ovulation induction with timed intercourse or intra-uterine insemination for subfertility associated with polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2011; (5).
 81. Nahuis MJ, Oosterhuis GJ, Hompes PG, van Wely M, Mol BW, van der Veen F. The basic fertility workup in women with polycystic ovary syndrome: a systematic review. *Fertil Steril.* 2013; 100(1):219-25.
 82. Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. *Arch Gynecol Obstet.* 2016; 293(3): 509-515.
 83. Nicholson F, Rolland C, Broom J, Love J. Effectiveness of long-term (twelve months) nonsurgical weight loss interventions for obese women with polycystic ovary syndrome: a systematic review. *Int J Women Health.* 2010; 2: 393-399.
 84. Palomba S, de Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. *Hum Reprod Update.* 2015; 21(5): 575-592.
 85. Parsanezhad ME, Zarei A, Sayadi M, Jaafarzadeh A, Rajaefard A, Frank V, et al. Surgical ovulation induction in women with polycystic ovary syndrome: a systematic review. *Iran J Med Sci.* 2009; 34(4): 225-241.
 86. Paul C, Lagana AS, Maniglio P, Triolo O, Brady DM. Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. *Gynecol Endocrinol.* 2016; 32(6): 431-438.
 87. Peitsidis P, Agrawal R. Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. *Reprod Biomed Online.* 2010; 20(4): 444-452.
 88. Peng CY, Xie HJ, Guo ZF, Nie YL, Chen J, Zhou JM, et al. The association between androgen receptor gene CAG polymorphism and polycystic ovary syndrome: a case-control study and meta-analysis. *J Assist Reprod Genet.* 2014; 31(9): 1211-1219.
 89. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Reprod Biol Endocrinol.* 2013; 11: 56.
 90. Rajender S, Carlus SJ, Bansal SK, Negi MP, Sadasivam N, Sadasivam MN, et al. Androgen receptor CAG repeats length polymorphism and the risk of polycystic ovarian syndrome (PCOS). *PLoS*

- One. 2013; 8(10): e75709.
91. Reis GV, Gontijo NA, Rodrigues KF, Alves MT, Ferreira CN, Gomes KB. Vitamin D receptor polymorphisms and the polycystic ovary syndrome: a systematic review. *J Obstet Gynaecol Res*. 2017; 43(3): 436-446.
 92. Ren LN, Guo LH, Ma WZ, Zhang R. A meta-analysis on acupuncture treatment of polycystic ovary syndrome. *Chen Tzu Yen Chiu*. 2014; 39(3): 238-246.
 93. Rocca ML, Venturella R, Mocchiari R, Di Cello A, Sacchinelli A, Russo V, et al. Polycystic ovary syndrome: chemical pharmacotherapy. *Expert Opin Pharmacother*. 2015; 16(9): 1369-1393.
 94. Saha L, Kaur S, Saha PK. N-acetyl cysteine in clomiphene citrate resistant polycystic ovary syndrome: A review of reported outcomes. *J Pharmacol Pharmacother*. 2013; 4(3): 187-191.
 95. San-Millan JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. *Clin Endocrinol (Oxf)*. 2010; 72(3): 383-392.
 96. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Brown J, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. *Cochrane Database Syst Rev*. 2016; (9).
 97. Sirmans SM, Weidman-Evans E, Everton V, Thompson D. Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications. *Ann Pharmacother*. 2012; 46(3): 403-418.
 98. Song LY, Luo JR, Peng QL, Wang J, Xie L, He Y, et al. Lack of association of INS VNTR polymorphism with polycystic ovary syndrome: a meta-analysis. *J Assist Reprod Genet*. 2014; 31(6): 675-681.
 99. Sun X, Zhang D, Zhang W. Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. *Arch Gynecol Obstet*. 2013; 288(2): 423-430.
 100. Taghavi SA, Bazarganipour F, Montazeri A, Kazemnejad A, Chaman R, Khosravi A. Health-related quality of life in polycystic ovary syndrome patients: a systematic review. *Iran J Reprod Med*. 2015; 13(8): 473-482.
 101. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome. *Cochrane Database Syst Rev*. 2009; (3): CD003053.
 102. Tang L, Xu L, Pan X, Zhang J, Wu T, Liu GJ. Ultrasound-guided transvaginal ovarian needle drilling for clomiphene-resistant polycystic ovarian syndrome in subfertile women. *Cochrane Database Syst Rev*. 2010; (11).
 103. Tang ST, Wang CJ, Tang HQ, Peng WJ, Wang YM, Zhang Q. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with polycystic ovary syndrome: a meta-analysis. *Mol Biol Rep*. 2012; 39(10): 9649-9660.
 104. Tang W, Wang Y, Jiang H, Liu C, Dong C, Chen S, et al. Insulin receptor substrate-1 (IRS-1) rs1801278G>A polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis. *Int J Clin Exp Med*. 2015; 8(10): 17451-17460.
 105. Tang YL, Yu J, Zeng ZG, Liu Y, Liu JY, Xu JX. Circulating omentin-1 levels in women with polycystic ovary syndrome: a meta-analysis. *Gynecol Endocrinol*. 2017; 33(3): 244-249.
 106. Thethi TK, Katalenich B, Nagireddy P, Chhabra P, Kuhadiya N, Fonseca V. Role of insulin sensitizers on cardiovascular risk factors in polycystic ovarian syndrome: a meta-analysis. *Endocr Pract*. 2015; 21(6): 645-667.
 107. Tomlinson J, Millward A, Stenhouse E, Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? *Diabet Med*. 2010; 27(5): 498-515.
 108. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. *Hum Reprod Update*. 2011; 17(6): 741-760.
 109. Tsikouras P, Spyros L, Manav B, Zervoudis S, Poiana C, Nikolaos T, et al. Features of polycystic ovary syndrome in adolescence. *J Med Life*. 2015; 8(3): 291-296.
 110. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. *Gynecol Endocrinol*. 2012; 28(7): 509-515.
 111. Wang LL, Ren W, Cheng QF, Fan XD. Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis. *Chung Hua Fu Chan Ko Tsa Chih*. 2012; 47(9): 659-663.
 112. Wang R, Goodarzi MO, Xiong T, Wang D, Azziz R, Zhang H. Negative association between androgen receptor gene CAG repeat polymorphism and polycystic ovary syndrome? A systematic review and meta-analysis. *Mol Hum Reprod*. 2012; 18(10): 498-509.
 113. Wang LH, Wang LM, Zhou N. 4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with polycystic ovary syndrome in Chinese patients: a meta-analysis. *Arch Gynecol Obstet*. 2015; 292(3): 683-636.
 114. Wang R, Kim BV, Zhang H, Moll E, Van Wely M, Johnson NP, et al. Clomiphene, metformin, letrozole, tamoxifen or combined clomiphene-metformin for polycystic ovary syndrome-a systematic review and individual participant data network meta-analysis. *Hum Reprod Update*. Conference: 32nd annual meeting of the european society of human reproduction and embryology Finland. 2016; 31: i441-i442.
 115. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. *J Clin Endocrinol Metab*. 2010; 95(5): 2038-2049.
 116. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. *Fertil Steril*. 2011; 95(3): 1073-1079. e1-11.
 117. Wojciechowski P, Lipowska A, Rys P, Ewens KG, Franks S, Tan S, et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. *Diabetologia*. 2012; 55(10): 2636-2645.
 118. Wu Y, Robinson N, Hardiman PJ, Taw MB, Zhou J, Wang FF, et al. Acupuncture for treating polycystic ovary syndrome: guidance for future randomized controlled trials. *J Zhejiang Univ Sci B*. 2016; 17(3): 169-180.
 119. Xian L, He W, Pang F, Hu Y. ADIPOQ gene polymorphisms and susceptibility to polycystic ovary syndrome: a HuGE survey and meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2012; 161(2): 117-124.
 120. Xian-Ling Z, Ya-Fei Z, Quan T, Yan X, Rui-Fang A, Zeng X-L, et al. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. *Medicine*. 2016; 95(36): 1-10.
 121. Xie GB, Xu P, Che YN, Xia YJ, Cao YX, Wang WJ, et al. Microsatellite polymorphism in the fibrillin 3 gene and susceptibility to PCOS: a case-control study and meta-analysis. *Reprod Biomed Online*. 2013; 26(2): 168-174.
 122. Xu X, Du C, Zheng Q, Peng L, Sun Y. Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. *BMC Womens Health*. 2014; 14: 93.
 123. Yu M, Feng R, Sun X, Wang H, Wang H, Sang Q, et al. Polymorphisms of pentanucleotide repeats (tttta)_n in the promoter of CYP11A1 and their relationships to polycystic ovary syndrome (PCOS) risk: a meta-analysis. *Mol Biol Rep*. 2014; 41(7): 4435-4445.
 124. Yu Y, Fang L, Zhang R, He J, Xiong Y, Guo X, et al. Comparative effectiveness of 9 ovulation-induction therapies in patients with clomiphene citrate-resistant polycystic ovary syndrome: a network meta-analysis. *Sci Rep*. 2017; 7(1): 3812.
 125. Zhang H, Bi Y, Hu C, Lu W, Zhu D. Association between the Pro12Ala polymorphism of PPAR-gamma gene and the polycystic ovary syndrome: a meta-analysis of case-control studies. *Gene*. 2012; 503(1): 12-17.
 126. Zhang TT, Yuan L, Yang YM, Ren Y. The -675 4G/5G polymorphism in the PAI-1 gene may not contribute to the risk of PCOS. *Eur Rev Med Pharmacol Sci*. 2014; 18(16): 2326-2331.
 127. Zhang S, Wang Y, Jiang H, Liu C, Sun B, Chen S, et al. Peroxisome proliferator-activated receptor gamma rs1801282 C>G polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis involving 7,069 subjects. *Int J Clin Exp Med*. 2015; 8(10): 17418-17429.
 128. Zheng J, Shan PF, Gu W. The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. *J Endocrinol Invest*. 2013; 36(10): 797-802.
 129. Abu Hashim H, Foda O, Ghayaty E. Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. *Acta Obstet Gynecol Scand*. 2015; 94(9): 921-930.
 130. Al Khalifah RA, Florez ID, Dennis B, Thabane L, Bassilious E. Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis. *Pediatrics*. 2016; 137(5): 1-12.
 131. Baghdadi LR, Abu Hashim H, Amer SA, Palomba S, Falbo A, Al-Ojaimi E, et al. Impact of obesity on reproductive outcomes after ovarian ablative therapy in PCOS: a collaborative meta-analysis. *Reprod Biomed Online*. 2012; 25(3): 227-241.

132. Bordewijk EM, Nahuis M, Costello MF, Van der Veen F, Tso LO, Mol BW, et al. Metformin during ovulation induction with gonadotropins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. *The Cochrane database Syst Rev.* 2017; 1: Cd009090.
133. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. *The Cochrane database Syst Rev.* 2016; 12: Cd002249.
134. Butterworth J, Deguara J, Borg CM. Bariatric Surgery, polycystic ovary syndrome, and infertility. *J Obes.* 2016; 2016: 1871594.
135. Ding N, Chang J, Jian Q, Liang X, Liang Z, Wang F. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Gynecol Endocrinol.* 2016; 32(11): 866-871.
136. Fang F, Ni K, Cai Y, Shang J, Zhang X, Xiong C. Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. *Complement Ther Clin Pract.* 2017; 26: 53-60.
137. Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2012; 6: CD001122.
138. Feng L, Lin XF, Wan ZH, Hu D, Du YK. Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. *Gynecol Endocrinol.* 2015; 31(11): 833-839.
139. Franik S, Kremer AMJ, Nelen LDMW, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2014; (10).
140. Dissemination CfRa. Does metformin combined with clomiphene citrate improve fertility related outcomes in clomiphene resistant women with PCOS: a systematic review (Provisional abstract). *DARE.* 2015; (2).
141. Graff SK, Mario FM, Ziegelmann P, Spritzer PM. Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. *Int J Clin Pract.* 2016; 70(6): 450-461.
142. He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. *Reprod Biomed Online.* 2011; 23(1): 91-96.
143. Huang X, Wang P, Tal R, Lv F, Li Y, Zhang X. A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. *Int J Gynaecol Obstet.* 2015; 131(2): 111-116.
144. Kollmann M, Martins WP, Lima ML, Craciunas L, Nastri CO, Richardson A, et al. Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2016; 48(6): 709-718.
145. Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. *Clin Endocrinol (Oxf).* 2011; 74(3): 332-339.
146. Luo S, Li S, Li X, Bai Y, Jin S. Effect of gonadotropin-releasing hormone antagonists on intrauterine insemination cycles in women with polycystic ovary syndrome: a meta-analysis. *Gynecol Endocrinol.* 2014; 30(4): 255-259.
147. Misso ML, Wong JL, Teede HJ, Hart R, Rombauts L, Melder AM, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. *Hum Reprod Update.* 2012; 18(3): 301-312.
148. Misso ML, Costello MF, Garrubba M, Wong J, Hart R, Rombauts L, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update.* 2013; 19(1): 2-11.
149. Moazami Goudarzi Z, Fallahzadeh H, Aflatoonian A, Mirzaei M. Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: A systematic review and meta-analysis. *Iran J Reprod Med.* 2014; 12(8): 531-538.
150. Palomba S, Pasquali R, Orio F, Jr., Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. *Clin Endocrinol (Oxf).* 2009; 70(2): 311-321.
151. Palomba S, Falbo A, Orio F, Jr., Zullo F. Effect of preconceptual metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. *Fertil Steril.* 2009; 92(5): 1646-1658.
152. Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotropins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. *BJOG.* 2013; 120(3): 267-276.
153. Palomba S, Falbo A, La Sala GB. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. *Reprod Biol Endocrinol.* 2014; 12: 3.
154. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? *Reprod Biomed Online.* 2012; 24(1): 6-22.
155. Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. *BJOG.* 2018; 125(3): 299-308.
156. Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. *Cochrane Database Syst Rev.* 2011; (10): CD008565.
157. Roque M, Tostes AC, Valle M, Sampaio M, Geber S. Letrozole versus clomiphene citrate in polycystic ovary syndrome: systematic review and meta-analysis. *Gynecol Endocrinol.* 2015; 31(12): 917-921.
158. Siebert TI, Viola MI, Steyn DW, Kruger TF. Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. *Gynecol Obstet Invest.* 2012; 73(4): 304-313.
159. Sinawat S, Buppasiri P, Lumbiganon P, Pattanittum P. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. *Cochrane Database Syst Rev.* 2008; (1): CD006226.
160. Siristatidis CS, Vrachnis N, Creatsa M, Maheshwari A, Bhattacharya S. In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. *Cochrane Database Syst Rev.* 2013; (10): CD006606.
161. Siristatidis C, Sergentanis TN, Vogiatzi P, Kanavidis P, Chrelias C, Papanтониou N, et al. In vitro maturation in women with vs. without polycystic ovarian syndrome: a systematic review and meta-analysis. *PLoS One.* 2015; 10(8): e0134696.
162. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. *Cochrane Database Syst Rev.* 2012; (5): CD003053.
163. Thakker D, Raval A, Patel I, Walia R. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. *Obstet Gynecol Int.* 2015; 2015: 1-13.
164. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2014; (11): CD006105.
165. Weiss NS, Nahuis M, Bayram N, Mol WB, Van der Veen F, van Wely M. Gonadotropins for ovulation induction in women with polycystic ovarian syndrome. *Cochrane Database Syst Rev.* 2015; (9): CD010290.
166. Xiao J, Chen S, Zhang C, Chang S. The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. *Gynecol Endocrinol.* 2012; 28(12): 956-960.
167. Xiao J, Chen S, Zhang C, Chang S. Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta analysis. *Gynecol Endocrinol.* 2013; 29(3): 187-191.
168. Xingrong T, Shengbing L, Ying C, Chao F, Hua L, Xingping Z, et al. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. *Clin Invest Med.* 2016; 39(4): E120-E31.
169. Zeng XL, Zhang YF, Tian Q, Xue Y, An RF. Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. *Medicine.* 2016; 95(36): e4526.
170. Zhang YY, Hou LQ, Zhao TY. Effects of acarbose on polycystic ovary syndrome: a meta-analysis. *Exp Clin Endocrinol Diabetes.* 2014; 122(6): 373-378.
171. Zhuang J, Wang X, Xu L, Wu T, Kang D. Antidepressants for polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2013; (5): CD008575.
172. Zhuo Z, Wang A, Yu H. Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. *J Diabetes Res.* 2014; 2014: 381231.